Drugs / JSKN022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07292402 | Oct 2025 → Aug 2027 expected | cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Results 康宁杰瑞两项双靶点ADC临床前研究数据在2025年AACR年会公布 alphamabonc.com ↗
临床前数据表明，JSKN022具有以下差异化特征： |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 康宁杰瑞两项双靶点ADC临床前研究数据在2025年AACR年会公布 alphamabonc.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JSKN022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07292402 ↗ |
| Route | Intravenous | “JSKN022 administered intravenously at selected dose levels according to protocol” NCT07292402 ↗ |